




The relative strengths and weaknesses of Aclaris Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 15% points. The greatest weakness of Aclaris Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 59% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	57,493
Cost of Goods Sold	5,133
Intangible Assets	7,123
Liabilities, Current	14,874
Liabilities, Non-Current	3,179
Other Assets	4,514
Other Compr. Net Income	-28
Other Expenses	-182
Other Liabilities	15,081
Other Net Income	-285
Other Revenues	6,482
Property and Equipment	1,654
Research and Development	31,731
Selling, General and Administrative Expense	20,530

Output Variable	Value in 1000 USD
Assets	70,784
Liabilities	33,134
Expenses	57,212
Revenues	6,482
Stockholders Equity	37,650
Net Income	-51,015
Comprehensive Net Income	-51,029
BaseVar	83,962
ECR before Limited Liability	60%
Economic Capital Ratio	197%